Abstract
Жигар циррози ва ГЦК СГС билан боғлиқ ўлимга энг кўп ҳисса қўшади, аммо сурункали HCV инфекциясининг жигардан ташқари намоён бўлиши ҳам катта ўзгариш ва салбий оқибатларга олиб келади. СГС нинг тизимли жигардан ташқари кўринишларининг патогенези кўп қиррали. В-лимфоцитларнинг узоқ муддатли стимуляцияси ҳам, криоглобулинемия ҳам тизимли касалликларнинг ривожланишига олиб келиши мумкин
References
Montoya, V. Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs / V. Montoya, AYM. Howe, WY. Dong, W. Dong, CJ. Brumme, AD. Olmstead et al. // Scientific Rep. - 2021. - Vol. 22, №1. doi: 10.1038/s41598-021-88132-8.
Mueller, PP. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication / PP. Mueller, Q. Chen, T. Ayer, NZ. Janjua, F. Kanwal, J. Chhatwal // Research article. - 2020. -Vol.77, №. 1. - P. 55-62.
Na, SK. Aspartate aminotransferase to-platelet ratio or FIB-4 index predicts the development of hepatocellular carcinoma in chronic hepatitis C patients with sustained virologic response to interferon therapy / SK. Na, SJ. Lee, YK. Cho, YN. Kim, EK. Choi, BC. Song et al. // J Interferon Cytokine Res. - 2019. - Vol.39, №11. - P. 703¬710.
Nahon, P. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals / P. Nahon, A. Cobat // Human Genetics. - 2020. - Vol. 139, №6-7. - P. 855¬863.
Nahon, P. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs / P. Nahon, R. Layese, V. Bourcier, C. Cagnot, P. Marcellin, D. Guyader, et al. // Gastroenterology. - 2018. - Vol.155, №5. - P. 1436 - 1450.
Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases / F. Negro // J Hepatol. - 2014. - Vol.61, №1. - P. 69¬78.